UK analysis firm crashes into administration – engaged on ‘reverse ageing’ | UK | News | EUROtoday

A UK-based biotechnology firm, centered on rejuvenation biology, has entered administration within the newest blow to the enterprise business. Clock.bio, primarily based at Cambridge Biomedical Campus, Cambridge, has a major mission to increase the wholesome human lifespan by figuring out and activating the physique’s innate genetic applications that may reverse mobile ageing.

Unlike conventional longevity corporations that target slowing down the ageing course of, Clock.bio goals to reverse it. They leverage the distinctive properties of human induced pluripotent stem cells (iPSCs) – the one human cells that may naturally reset their organic clock – to review how ageing will be undone at a molecular stage.

It was based in 2020 by Mark Kotter (a neurosurgeon and biologist on the University of Cambridge) and Koby Baranes. However, on March 19, a discover was printed on the London Gazette web site, saying that joint directors had been appointed.

According to The Gazette discover, on March 19, Geoffrey Paul Rowley and Philip Lewis Armstrong, each of FRP Advisory Trading Limited, had been appointed directors. Once the appointment is filed, a authorized protect (moratorium) is positioned across the firm. Once that is in place, collectors are frozen – they can not begin or proceed authorized proceedings, seize property, or wind up the corporate with out the court docket’s permission.

Appointing directors permits the enterprise to proceed working, if viable, with out the quick menace of being pressured into liquidation. The powers of the corporate’s administrators are additionally suspended.

According to the Companies House submitting historical past for Clock Bio Limited, the corporate has seen vital modifications in its board and govt management over the past 12 months. On December 31, Markus Gstöettner terminated his appointment as a director, whereas in July, the corporate appointed Dr Michael Karl Boehler and Dr Piotr Romanowski to the board.

On March 5, the corporate filed its full accounts for the 12 months ending December 31, 2025. They proceed to file “Total Exemption Full Accounts,” which is typical for early-stage biotech startups. This means they qualify as a small firm and will not be but required to have their accounts audited. In June 2024, the corporate moved its registered workplace to Salisbury House, Station Road – a primary location within the Cambridge biotech hub and nearer to the college.

The firm has constructed a discovery engine primarily based on three fundamental pillars:

1. GeneAge (Atlas of Rejuvenation) – A genome-wide map figuring out the precise genes liable for rejuvenation. They have already recognized over 140 candidate genes that drive age reversal.
2. ImAge – An AI-powered instrument that measures a cell’s organic age utilizing single-cell imaging. This permits speedy, high-throughput testing to find out whether or not a remedy is definitely making cells youthful.
3. ClinAge – A medical validation platform designed to maneuver findings into human trials shortly. They are beginning with pores and skin topicals and nutraceuticals as a quicker path to market earlier than shifting to systemic therapies for age-related ailments.

Clock.bio employs a dual-track technique that mixes the repurposing of current protected molecules to set off rejuvenation genes with the event of totally new gene therapies. By partnering with pharmaceutical corporations, they goal to deal with complicated age-related situations, akin to Alzheimer’s and Parkinson’s, by means of each quick and long-term medical options.

The Express contacted clock.bio and FRP Advisory Trading Limited for remark.